Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication January 12, 2018
- Accepted for publication May 14, 2018
- Published online January 2, 2019.
Article Versions
- previous version (June 7, 2018 - 08:01).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Talakad G. Lohith1,
- Idriss Bennacef1,
- Rik Vandenberghe2,
- Mathieu Vandenbulcke2,
- Cristian A. Salinas1,
- Ruben Declercq3,
- Tom Reynders3,
- N. Florestina Telan-Choing4,
- Kerry Riffel1,
- Sofie Celen5,
- Kim Serdons6,
- Guy Bormans5,
- Kuenhi Tsai7,
- Abbas Walji8,
- Eric D. Hostetler1,
- Jeffrey L. Evelhoch1,
- Koen Van Laere6,
- Mark Forman9,
- Aubrey Stoch9,
- Cyrille Sur1 and
- Arie Struyk9
- 1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
- 2Neurology Department, University Hospitals Leuven, Leuven, Belgium; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium; Alzheimer Research Centre, KU Leuven, Leuven Institute for Neuroscience and Disease, Leuven, Belgium
- 3Translational Pharmacology Europe, Merck Sharp & Dohme Corp., Brussels, Belgium
- 4Translational Pharmacology Clinical Operations, Merck & Co., Inc., North Wales, Pennsylvania
- 5Radiopharmaceutical Research, KU Leuven, Leuven, Belgium
- 6Division of Nuclear Medicine, University Hospitals Leuven and UZ Leuven, Leuven, Belgium
- 7Early Clinical Statistics, Merck & Co., Inc., West Point, Pennsylvania
- 8Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania; and
- 9Translational Pharmacology, Merck & Co., Inc., North Wales, Pennsylvania
- For correspondence or reprints contact: Arie Struyk, Merck & Co., Inc., 351 N. Sumneytown Pike, Mailstop UG4D-48, North Wales, PA 19454. E-mail: arie_struyk{at}merck.com